4D Molecular Therapeutics Inc Reports Full Year 2023 Financial Results [Yahoo! Finance]
4D Molecular Therapeutics, Inc. (FDMT)
Company Research
Source: Yahoo! Finance
Net Loss : Net loss decreased to $100.8 million in 2023 from $107.5 million in 2022. Research and Development Expenses : R&D expenses rose to $97.1 million, reflecting the progression of clinical trials. Cash Position : Cash, cash equivalents, and marketable securities were $299 million as of December 31, 2023, bolstered by a successful public offering. Operational Runway : The company's cash position is expected to fund operations into the first half of 2027. Strategic Partnerships : Entered agreements with Astellas Pharma and Arbor Biotechnologies, validating 4DMTs Therapeutic Vector Evolution platform. Clinical Milestones : Positive interim data for 4D-150 in wet AMD and other product candidates, with Phase 3 initiation expected in Q1 2025. Warning! GuruFocus has detected 5 Warning Signs with FDMT. On February 29, 2024, 4D Molecular Therapeutics Inc ( NASDAQ:FDMT ) released its 8-K filing , announcing its full-year financial results for 2023 and providing updates on
Show less
Read more
Impact Snapshot
Event Time:
FDMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FDMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FDMT alerts
High impacting 4D Molecular Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FDMT
News
- 4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release [Yahoo! Finance]Yahoo! Finance
- 4DMT Announces Presentations at ARVO 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- 4DMT Announces Presentations at ARVO 2024 Annual MeetingGlobeNewswire
- 4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution [Seeking Alpha]Seeking Alpha
- Ophthalmics Collaboration and Licensing Deals Collection, 2019-2024: Leading Deals by Value, Most Active Dealmakers, Benchmark Analysis, Financial Terms, and More [Yahoo! Finance]Yahoo! Finance
FDMT
Earnings
- 11/9/23 - Beat
FDMT
Sec Filings
- 4/18/24 - Form 4
- 4/10/24 - Form ARS
- 4/10/24 - Form DEFA14A
- FDMT's page on the SEC website